Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2018

  • ID: 4518496
  • Drug Pipelines
  • 173 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Biofrontera AG
  • Cannabis Science Inc
  • Genextra Spa
  • Ignyta Inc
  • MediGene AG
  • MORE
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2018, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline landscape.

Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scaly, brown or flesh-colored patch and white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery.

Report Highlights:

This latest pipeline guide Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 7, 4 and 4 respectively.

Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc
  • Biofrontera AG
  • Cannabis Science Inc
  • Genextra Spa
  • Ignyta Inc
  • MediGene AG
  • MORE
Introduction

Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview

Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Development

Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment

Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development

Basal Cell Carcinoma (Basal Cell Epithelioma) - Drug Profiles

Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects

Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products

Basal Cell Carcinoma (Basal Cell Epithelioma) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Amgen Inc, H1 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biofrontera AG, H1 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biosceptre International Ltd, H1 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Cannabis Science Inc, H1 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Genextra Spa, H1 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Ignyta Inc, H1 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Laboratories Ojer Pharma SL, H1 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by MediGene AG, H1 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Medivir AB, H1 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Merck & Co Inc, H1 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Provectus Biopharmaceuticals Inc, H1 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Transgene SA, H1 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H1 2018

Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products, H1 2018

List of Figures

Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Adgero Biopharmaceuticals Holdings Inc
  • Amgen Inc
  • Biofrontera AG
  • Biosceptre International Ltd
  • Cannabis Science Inc
  • Genextra Spa
  • Ignyta Inc
  • Laboratories Ojer Pharma SL
  • MediGene AG
  • Medivir AB
  • Merck & Co Inc
  • Provectus Biopharmaceuticals Inc
  • Regeneron Pharmaceuticals Inc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Transgene SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll